Advanced control strategies towards the intensification of monoclonal antibody production
Conference Paper
Overview
Identity
Additional Document Info
View All
Overview
abstract
Process intensification plays a dominant role in the improvement of sustainability and productivity of biopharmaceutical processes. In particular, during the past few years there has been increasing demand on product quality and higher titers in the production of monoclonal antibodies (mAbs) [1]. The latter consists of two main parts: (1) the upstream processing (USP), where the cells are cultured and the therapeutic agent is produced and (2) the downstream processing (DSP) that involves the isolation/purification of the targeted product. Both the upstream and the downstream processing, however, are affected by various parameters related to the design of the bioreactor, the methods chosen for separation/purification as well as the operation mode (e.g. batch or continuous).
